Naltima 50 is a generic oral formulation of naltrexone 50mg, a well-established opioid antagonist used in the long-term management of both alcohol and opioid dependence. It works by competitively binding to opioid receptors in the brain, particularly the mu-opioid receptor, preventing the euphoric and reinforcing effects of alcohol and opioids. Unlike agonist-based treatments such as methadone or buprenorphine, naltrexone is non-addictive and does not cause physical dependence. Naltima 50 is most effective in patients who have completed detoxification and are motivated to stay abstinent. It plays a crucial role in relapse prevention and long-term sobriety by suppressing cravings and dampening the brain's reward response to addictive substances. In low doses (LDN), naltrexone is under investigation for its ability to reduce inflammation and modulate mood, offering potential benefits in conditions such as depression, chronic pain, and autoimmune disorders. This broad therapeutic versatility makes Naltima 50 a valuable tool in mental health and substance use disorder management.

- Sleep & Mental Health > Alcoholism Used as a daily maintenance treatment to reduce cravings and relapse rates in patients with alcohol use disorder by blocking reward-related brain activity. - Sleep & Mental Health > Depression (Low-Dose Naltrexone) In low doses, naltrexone is being researched for its potential in alleviating treatment-resistant depression and inflammatory mood disorders by modulating microglial activity and immune response. - Sleep & Mental Health > Obsessive-Compulsive Disorder (OCD) Explored as an adjunctive therapy to reduce compulsive behaviors and intrusive thoughts in patients with refractory OCD.

Naltrexone acts as a full antagonist at opioid receptors, especially the mu-receptor, thereby blocking the effects of endogenous and exogenous opioids. In the treatment of alcohol dependence, naltrexone disrupts the brain's reward circuitry that reinforces drinking behavior. By eliminating the pleasurable response, it helps reduce the urge to drink and supports abstinence. In opioid dependence, it prevents relapse by making opioid use ineffective. In low doses (LDN), it may modulate immune function, reduce neuroinflammation, and restore endorphin balance, potentially benefiting a range of psychiatric and inflammatory conditions. Naltima 50 offers a non-sedating, non-euphoric alternative that helps maintain long-term recovery and emotional stability.

Usual Adult Dose for Alcohol Dependence (Oral): → 50 mg orally once daily Duration of therapy: Minimum 12 weeks, can be extended based on individual recovery goals. Usual Adult Dose for Alcohol Dependence (Intramuscular): → 380 mg IM once every 4 weeks / month Usual Adult Dose for Opiate Dependence (Oral): → Initial dose: 25 mg orally once daily → Maintenance dose: 50 mg orally once daily (if tolerated without withdrawal) Usual Adult Dose for Opiate Dependence (Intramuscular): → 380 mg IM once every 4 weeks / month Comments: - A minimum opioid-free period of 7 to 14 days is required before starting naltrexone to prevent precipitated withdrawal. - Patients transitioning from buprenorphine or methadone must be carefully monitored. - Management of potential withdrawal symptoms may require non-opioid medications. - Treatment success depends on strict adherence and incorporation into a comprehensive relapse prevention program that includes behavioral therapy and support systems.

Store below 25°C in a dry, dark environment. Keep away from humidity, sunlight, and heat sources. Ensure the product is kept in its original container and stored securely out of reach of children.

Common side effects: nausea, headache, anxiety, insomnia, tiredness Less common: decreased appetite, joint or muscle pain, abdominal cramps, mood swings Rare but serious: liver inflammation, hypersensitivity reactions, suicidal ideation, depression Liver function monitoring and regular psychiatric evaluations are advised during long-term therapy.